Answers are grounded in this paper and cite their sources.
Objective Whether immune checkpoint inhibitor (ICI)-based regimens confer a survival benefit over chemotherapy (CT) alone in advanced/recurrent endometrial cancer (EC), particularly by mismatch repair status, remains inconclusive. We conducted an individual patient data (IPD) meta-analysis of randomized trials comparing ICI-based regimens vs. CT alone to quantify survival benefits and assess safety.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: